GenesisCare & Vision RT Announce Expansion of Global Strategic Partnership
Establishing Surface-Guided Radiation Therapy as the Standard of Care in Advanced Radiation Delivery
GenesisCare, one of the largest providers of integrated cancer care globally, and Vision RT, the inventor of and a market leader in Surface Guided Radiation Therapy (SGRT), have announced an expansion of their global strategic partnership.
This new agreement will see Vision RT provide GenesisCare with 30 new AlignRT systems, with potential for an additional 10, over the course of the next 2-3 years. Patients in GenesisCare centers in Australia, US, UK, and Spain are set to benefit from this agreement, with the first orders under this new contract currently being shipped. Once fully installed, this will expand the fleet of Vision RT systems within the GenesisCare network.
AlignRT offers a complete solution for high precision patient positioning throughout therapy to improve the accuracy of set-up and treatment. In traditional radiation therapy, cancer patients receive tattoos and other permanent marks to ensure treatment is delivered to a precise location. AlignRT uses 3D stereoscopic camera units and surface tracking to detect slight movements, automatically pausing treatment as needed, to safely deliver highly targeted tattoo-free radiation therapy. The technology is non-invasive and can be used for patients with any forms of cancer, including breast, brain, lung, liver, or head and neck cancer or sarcoma.
GenesisCare will expand its use of AlignRT technology by continuing to reach new patients with the help of Vision RT’s patient education website, SaferRadiationTherapy.com. The site supports the referring provider community through a patient education toolkit with marketing resources to educate and inform local providers and their patients.
“Vision RT and GenesisCare have been partnering for the past 3 years, and we have seen how AlignRT has significantly impacted the quality and efficiency of their radiotherapy treatments,” said Dr Norman Smith, CEO of Vision RT. “We are delighted that due to this success, the rollout within the GenesisCare network has been three times faster than expected. We’re thrilled that they have now decided to expand and deepen our partnership as AlignRT is standardised across their global fleet of linear accelerators.”
GenesisCare Global Chief Medical Officer Wally Curran, MD said: “GenesisCare’s expanded partnership with Vision RT will increase patient access across our network to the latest advances in SGRT. This will enable us to continue to provide the best possible life outcomes for our patients.
“The expansion of AlignRT systems across our global network will provide more patients with highly precise, tattoo-free radiation therapy and can minimize radiation exposure to the heart and other surrounding healthy tissue.”
___
About Vision RT
Vision RT defines the standard of care in Surface Guided Radiation Therapy (SGRT). With 113 granted patents plus +40 pending, Vision RT continues to innovate in the radiation oncology space and is committed to making SGRT the standard of care for all patients. There are more than 1,900 systems installed worldwide.
SGRT, pioneered by Vision RT, uses proprietary 3D stereo camera units to monitor a patient’s skin surface in real-time and compare it to the ideal position with sub-millimetric accuracy. This ensures that radiation is delivered only when a patient is correctly positioned, enhancing safety and comfort. AlignRT is non-invasive and completely non-contact, an increasingly important advantage for cancer patients, who often have weakened immune systems.
AlignRT is being used by all 15 of the top 15 “Best Hospitals for Cancer” according to the latest analysis by U.S. News and World Report.
Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 23,000 people, and total revenue of around $4.2 billion.
About GenesisCare
Headquartered in Sydney, Australia, GenesisCare is a global healthcare company and one of the world’s largest integrated oncology organisations. The company’s purpose is to design care experiences that get the best possible life outcomes. This is grounded in the belief that care should be focused on the individual, not the condition.
GenesisCare is the world’s largest provider of radiotherapy – a vital treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. With a growing research and trials program numbering more than 150 clinical trials, a contract research organisation, and global innovation programs focused on precision medicine and novel therapies, GenesisCare aims to bring new therapies to more patients in need in a more affordable way.
Every year, GenesisCare clinical teams see more than 400,000 people at more than 440 locations, for cancer treatment, that includes more than 300 locations in the U.S., 40 locations in Australia, 14 in the UK, and 16 in Spain, with more than 30 new centres under development. The organisation employs more than 6000 highly trained physicians, healthcare professionals and support staff across Australia, Europe and now the U.S. GenesisCare also offers cardiology and sleep services at more than 80 locations across Australia. For more information, visit www.genesiscare.com.